We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Lisata Therapeutics Inc | NASDAQ:LSTA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.75 | 2.50 | 3.13 | 2.76 | 2.74 | 2.74 | 181 | 22:16:11 |
H.C. Wainwright 25th Annual Global Investment Conference
September 11-13 | New York City, NY
Dr. Mazzo’s presentation will be available on-demand on September 11, 2023, at 7:00 a.m. Eastern Time. Management will also participate in one-on-one meetings with investors on September 11th. For more information about the H.C. Wainwright 25th Annual Global Investment Conference, please visit https://hcwevents.com/annualconference/#toggle-id-5.
LSX World Congress USA
September 13-14 | Boston, MA
Dr. Mazzo will deliver a live presentation on Thursday, September 14, 2023, at 11:00 a.m. Eastern Time. Management will also participate in one-on-one meetings with investors on September 14th. For more information about the LSX World Congress USA, please visit https://www.lsxleaders.com/lsx-usa-congress.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata’s CendR Platform® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. For more information on the Company, please visit www.lisata.com.
Contact:
Investors and Media:
Lisata Therapeutics, Inc.John MendittoVice President, Investor Relations and Corporate CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com
1 Year Lisata Therapeutics Chart |
1 Month Lisata Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions